Triton has successfully spun-off a number of entities originally incubated at the company. These companies range for conductive organic polymers, nanotherapeutic cancer therapies, biological sensors, microelectronics, to high temperature bonding materials for industrial applications - just to name a few. The companies Triton has spunoff are:
FRX Polymers, LLLP (www.frxpolymers.com)
FRX Polymers, LLLP (FRX) has been formed as a new company to commercialize a new family of polyphosphonate homopolymers and copolymers. FRX will find initial markets as polymeric flame retardant additives for plastics and as transparent, high flowing, non-burning specialty polymers. FRX polymers are non-halogenated, phosphorous based polymers and have the highest Limiting Oxygen Index (LOI) of all commercial thermoplastics. (LOI is a key metric to determine non-burning characteristics of polymers.)
FRX polymers have three distinguishing properties. They have excellent flame retarding properties, they are transparent and also have very high melt flow rate. In addition, due to their polymeric nature, they will not migrate out of the host plastic when used as additives. Tests also show that in certain polymer systems, improved mechanical properties – such as heat distortion temperature – can result.
Aduro Biotech , Inc.
UPDATE - 2008: Triton BioSystems, Inc. has recently merged with Oncologic of Berkley, CA to form Aduro BioTech. For more information contact the website at www.adurobiotech.com
Aduro Biotech is focused on the development of non-invasive targeted therapeutics that use heat to treat cancer. The Company has leveraged its experience with magnetic nanomaterials and magnetic field energy, to make antibodies tumoricidal and more therapeutically selective, without the side effects of conventional therapies. Aduro is developing a revolutionary targeted anticancer therapy that uses localized lethal heat to treat late-stage cancers such as breast, lung, ovarian and prostate cancers. The Company's product is referred to as the Targeted Nano-Therapeutics™ (TNT™) System. The Company is in its pre-clinical stage and expects to begin human clinical trials in 2010.
Sensera, Inc. (www.sensera.com)
Sensera, Inc., of Chelmsford Massachusetts, is a development stage biological sensor company developing products for the point of care (POC) clinical diagnostics market. The Company has a unique sensor array technology that allows rapid, highly sensitive detection of proteins and DNA sequences. The technology is protected by four patents and features femtomolar sensitivity, allowing it to detect proteins like cardiac markers at a concentration at least an order of magnitude lower than current state-of-the-art assays. Sensera is incorporating this technology into a Point of Care (POC) Early & Rapid Analyzer (ER-A) to address unmet needs in the field of emergency medicine. Sensera is positioning the (ERA) to initially address one rapidly growing market: Early Diagnosis of Myocardial Injury. ERA’s high sensitivity for myocardial infarction indicators will enable the diagnosis of heart attacks (acute myocardial infarction or AMI) within two hours of the onset of chest pain, much earlier than possible with current tests. This eliminates the need for emergency personnel to wait for 6 hours in order to treat life-threatening AMI. The Company is currently in its product development stage.
SI2 Technologies (www.si2technologies.com)
SI2 Technologies, Inc. (SI2), a developer of advanced multifunctional electronic systems and components for high performance applications, was incorporated January 2003 as a high-technology development, small business (C Corporation) focused on transitioning these technologies into broader commercial markets. Our advanced, integrated multifunctional structures and devices serve commercial, industrial and government customers.